Amp Study Issue Antibody Mediated Prevention
Total Page:16
File Type:pdf, Size:1020Kb
VOLUME 17, ISSUE 1: JUNE 2017 THE AMP STUDY ISSUE ANTIBODY MEDIATED PREVENTION A NEW HOPE IN THE PERUVIAN AMAZON COMMUNITY ENGAGEMENT IN LIMA, PERU HVTN VISIBILITY IN FAITH COMMUNITIES ENGAGING AFRICAN AMERICAN COMMUNITIES AMP VIDEOS Cover Image Credit: Fly Machine Picture Co. Picture Machine Fly Credit: Image Cover A LETTER FROM THE EDITOR, STEPHAUN E. WALLACE Welcome to the newest edition of the The best part for us is when we hear HIV Vaccine Trials Network (HVTN) from you, the HVTN community. We Community Compass, formerly known thank you for your previous feedback, as the CAB Bulletin. I am thankful to the and continue to welcome your feedback HVTN community for their support in about how we are doing. Please help my transition into this role, and for their us ensure that this publication is continued dedication to supporting the representative of our entire global HVTN engagement of global communities in community! HVTN members (who have HIV prevention research. It makes me access to the HVTN member’s website) proud to say that I work for, and with, Stephaun E. Wallace, Editor-in-Chief can use our newly developed submission such an amazing research network and with so many page that offers the ability to submit topics and articles passionate and dedicated colleagues and friends. for inclusion in future issues. More information about this follows on page 11 under the “Meet the Community As you will see in this issue, Community Compass has Compass Team” section. undergone a transformative change, not just in design but also in its “feel,” in order to make it more accessible But indeed, it is YOU we have to thank: for your to our global communities. We hope to deliver an array support of the HVTN wherever you are in the world, of topics and information that encompass our HVTN for the work that you do, in whatever your role in the community globally as well as relevant information from HVTN community, and the impact we’ve been able our network partners as appropriate. HVTN Community to make on our collective history and communities, Compass had previously been known as a “newsletter,” together. and with the changes, we have adopted the term “magazine” to describe this publication going forward. There is so much more work to do to get us to an HIV vaccine, which we continue to believe is the best long- There are many important HVTN studies in the field, term hope for ending the HIV epidemic. The HVTN and in this issue, Community Compass focuses on the Community Compass team wants to be everywhere AMP Studies. These two studies span the globe and are you are, so please share with us what’s happening groundbreaking and innovative trials that will answer at your research sites, institutions, and in your very important questions. The answers may lead not only communities, so that we can share it with the world. to expanded research into the ways that antibodies may be used to fight HIV, but may also uncover new pathways Be well, that contribute to the development of an HIV vaccine. Stephaun E. Wallace Editor-in-Chief, HVTN Community Compass Editor-in-Chief: Production & Distribution: COMMUNITY COMPASS Stephaun E. Wallace Nina Feldman A PUBLICATION OF THE HIV VACCINE TRIALS NETWORK Layout & Design: Contributing Editors: The HIV Vaccine Trials Network is an international multi–disciplinary Cody Shipman Gail Broder collaboration. Support for the HVTN comes from the National Institute of Allergy and Infectious Diseases (NIAID) of the U.S. National Institutes SEND INQUIRIES ABOUT THIS ISSUE OF COMMUNITY COMPASS of Health, an agency of the U.S. Department of Health and Human TO: Stephaun E. Wallace, [email protected] Services. The Network and NIAID have a close, cooperative working relationship, with shared attention to intellectual and scientific issues. ABOUT COMMUNITY COMPASS VIEW PAST ISSUES OF COMMUNITY COMPASS AT The Community Compass aims to keep the HVTN community informed hvtn.org/en/community/community-compass.html about the Network’s research, site activities, and advances in the field of HIV prevention and vaccination. We encourage community members to submit news and event reports to this newsletter, and make this a true community sharing platform. FOLLOW US ON: twitter.com/helpendhiv Translations in Spanish, Portuguese and French provided by Northwest facebook.com/helpendhiv Translations, Inc. www.nwtranslations.com 2 HIV VACCINE TRIALS NETWORK | COMMUNITY COMPASS | VOLUME 17, ISSUE 1: JUNE, 2017 AMP STUDY ANTIBODY MEDIATED PREVENTION By: Dr. Shelly Karuna-HVTN, Seattle, WA, USA with contributions from the AMP Protocol Team The AMP (Antibody Mediated Prevention) Studies are a pair of efficacy trials—HVTN 703/HPTN 081 and HVTN 704/HPTN 085— that represent a landmark, global effort in HIV prevention. The studies explore whether a broadly neutralizing antibody, given as an intravenous (IV) infusion every 8 weeks over about two years, can prevent HIV infection and if so, how much of the antibody is needed to achieve HIV protection. The multi-stakeholder develop- Clinical trial sites have reported The Vaccine Research Center ment of the AMP Studies was enormous enthusiasm for AMP (VRC) developed the antibody, extensive. We were motivated among their collaborators and called VRC01, being evaluated by the continued impact of the potential participants in their in AMP. Study participants are HIV epidemic in spite of recent communities. Community randomly assigned to receive advances in HIV prevention and engagement efforts began either placebo or one of two doses treatment. We are inspired by the months before the trials opened of VRC01 (10mg/kg or 30 mg/kg). potential contribution of this new and remain strong. A team of HIV prevention approach. AMP’s dedicated laboratory, statistical, The studies will enroll 1,500 implementation has continued data management, Core women in sub-Saharan Africa on an ambitious trajectory. operations and clinical staff (HVTN 703/HPTN 081) and 2,700 The first participants enrolled based in the US, Peru, South men and transgender people in March 2016, and from the Africa, Zimbabwe, and beyond who have sex with men in North beginning enrollment rates are supporting committed and South America and Europe have exceeded projections. community educators, recruiters, (HVTN 704/HPTN 085). CAB members, clinicians, data As we go to print, near the one- managers, laboratory technicians, The trials are being conducted year anniversary of the trials’ investigators, coordinators, collaboratively by 47 trial sites openings, over 950 men and and many others at the 47 working with two clinical trials transgender individuals have sites conducting AMP globally. groups, the HIV Vaccine Trials enrolled in HVTN 704/HPTN Together with our inspiring Network and the HIV Prevention 085 and over 500 women have study participants, the AMP Trials Network, both of which enrolled in HVTN 703/HPTN 081. Studies are “turning up the are funded by the US National volume” on this new frontier Institutes of Health (NIH). The As the first participants enrolled in HIV prevention, propelling results are expected to inform begin to cross the halfway mark the HIV vaccine and prevention the HIV vaccine field and the of their trial participation, retention fields forward, moving us all HIV prevention field at large. (participant attendance at any type toward an AIDS-free generation. of study visit) remains at or above 96% in both trials and adher- * Dr. Shelly Karuna is the Director of Clinical Development for the HVTN and the ence (participant receipt of their Protocol Team Leader for the AMP Studies. scheduled infusion) remains at or above 99%. HVTN 703/HPTN 081 HVTN 704/HPTN 085 HIV VACCINE TRIALS NETWORK | COMMUNITY COMPASS | VOLUME 17, ISSUE 1: JUNE, 2017 3 COMMUNICATIONS AND COMMUNITY ENGAGEMENT UPDATE By: Jim Maynard- HVTN, Seattle, WA, USA Congratulations to Nandi Luthuli, complaining. Nandi is a joy to Lead Community Education work with, both personally and Training Manager in our professionally, and we celebrate our Johannesburg office, who was good fortune by having her play a a recipient of the 2016 Omololu critical role in our Network. Jim Maynard Falobi Award for Excellence in HIV Prevention Research Community The HVTN’s Community SOUTH AFRICA Advocacy! This award was Engagement Unit (CEU) is also IMPLEMENTATION UPDATE established by AVAC to pay tribute excited to welcome another new to the life and work of Omololu member, Stephaun Wallace who Falobi and to highlight the essential started in October 2016 and will role of community advocacy in be working closely with Gail HIV prevention research. Omololu Broder as our newest Senior Falobi was a visionary leader who Community Engagement Project continues to inspire many people Manager. Stephaun comes to us and projects. Over ten years ago from HANC where he was the on October 5, 2006, Omololu Legacy Project Manager. Stephaun died in a tragic accident. He was is an established and highly Dr. Zvavahera (Mike) Chirenje - UZ-UCSF a leading HIV/AIDS activist, an regarded leader within the House advocate for prevention research, Ball community internationally, and an excellent journalist. This and has led significant efforts to award honors individuals who have engage Historically Black Colleges shown leadership and commitment and Universities as well as faith to HIV prevention research communities nationally. Stephaun advocacy and inspired others to has more than 16 years in the field action. Nandi was profiled and of public health and more than honored at the HIV Research for two decades experience engaging Prevention (R4P) Conference that communities around education and Meeting participant with Dr. Glenda Grey was held in Chicago in October 2016. health issues. Stephaun holds many degrees, including master’s degrees The 2016 Award was awarded to in management and organizational a number of recipients to mark leadership and is an epidemiology a “Celebration of HIV Prevention PhD candidate.